Imm system traps vs. resistant bacteria in lab
Part of Infections clinical trials.
This lab study tests how certain immune system traps (NETs) kill a tough type of bacteria that is resistant to many antibiotics. It may help find new ways to treat infections that are hard to cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your sample must have a Pseudomonas aeruginosa infection that does not respond to carbapenem antibiotics.
- The bacteria must be collected from a wound, sputum, urine, or blood sample.
- The bacteria must not be sensitive to carbapenem antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibiotic combination (ceftazidime-avibactam) for people with difficult-to-treat Klebsiella pneumoniae infections that are resistant to carbapenem antibiotics due to a specific enzyme. It may help if you have a skin, chest, surgical wound, or urinary tract infection from this resistant bacteria.
This research study examines how certain bacteria become resistant to multiple antibiotics and develop protective biofilms. Researchers will study samples from patients with hospital-acquired infections to better understand why some bacteria survive antibiotics and how to fight them in the future.
This study tests different antibiotic combinations for severe infections caused by hard-to-treat Gram-negative bacteria (like Pseudomonas or Acinetobacter). The goal is to find the best treatment for bloodstream infections or pneumonia that started in the hospital.
This trial is testing a new way to use special tests (called integrons) to help doctors decide if they can safely use fewer strong antibiotics for urinary tract infections that are resistant to common treatments. It is for people in the hospital who have a resistant infection and may help reduce side effects and prevent more resistance.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
Hear when a new Neutrophil Extracellular Traps Formation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.